Understanding how alphaviruses infect and adapt in humans and mosquitoes
Mechanisms of alphavirus infectivity and adaptation - Resubmission - 1
This study is looking at how the Chikungunya virus spreads in people and mosquitoes, focusing on changes in the virus that make it more infectious, with the hope that what we learn can help create better treatments for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11031324 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which the Chikungunya virus (CHIKV) infects humans and mosquitoes, focusing on specific mutations in the virus's glycoproteins that enhance its infectivity. By studying these viral adaptations in a laboratory setting, researchers aim to uncover how these changes affect the virus's ability to spread and cause disease. The approach includes examining the interactions between viral proteins and their hosts, as well as how environmental factors influence these processes. Patients may benefit from insights gained that could lead to the development of new antiviral therapies.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals at risk of infection from alphaviruses, particularly those living in areas where these viruses are prevalent.
Not a fit: Patients who are not at risk of alphavirus infections or those with existing immunity may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective antiviral treatments for diseases caused by alphaviruses.
How similar studies have performed: Other research has shown success in understanding viral mechanisms and developing antiviral strategies, indicating that this approach has potential for meaningful advancements.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Stapleford, Kenneth — New York University School of Medicine
- Study coordinator: Stapleford, Kenneth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.